New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points

Gastric Cancer

Volumn 14, Issue 2, 2011, Pages 97-100

  Sano, Takeshi ^a   Aiko, Takashi ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; HISTOLOGY; HUMAN; JAPANESE; LOWER ESOPHAGUS SPHINCTER; LYMPHADENECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT INDICATION;

HUMANS; JAPAN; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; STOMACH NEOPLASMS;

EID: 79959380640     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0040-6     Document Type: Article

References (19)

1. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011. doi: 10.1007/s10120-011- 0041-5.
2. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2010 (ver. 3). Gastric Cancer 2011. doi: 10.1007/s10120-011-0042-4.
3. T Kajitani Japanese Research Society for the Study of Gastric Cancer 1981 The general rules for gastric cancer study in surgery and pathology Jpn J Surg 11 127 145 7300058 10.1007/BF02468883 1:STN:280:DyaL38%2FlsF2ksw%3D%3D (Pubitemid 11080134)
4. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English edition. Tokyo: Kanehara; 1995.
5. Japanese Gastric Cancer Association 1998 Japanese classification of gastric carcinoma: 2nd English edition Gastric Cancer 1 10 24 11957040 10.1007/PL00011681
6. T Nakajima 2002 Gastric cancer treatment guidelines in Japan Gastric Cancer 5 1 5 12021853 10.1007/s101200200000
7. International Union Against Cancer. In: Sobin LH, Gospodarowicz, MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. New Jersey: Wiley-Blackwell; 2009.
8. HS Ahn HJ Lee S Hahn, et al. 2010 Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer classification of gastric adenocarcinoma in comparison with the sixth classification Cancer. 116 5592 5598 20737569 10.1002/cncr.25550
9. Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 2009;6:71-94.
10. JJ Bonenkamp I Songun J Hermans, et al. 1995 Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients Lancet 345 745 748 7891484 10.1016/S0140-6736(95)90637-1 1:STN:280: DyaK2M7pvVClsg%3D%3D
11. A Cuschieri P Fayers J Fielding, et al. 1996 Post-operative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial Lancet 347 995 999 8606613 10.1016/S0140-6736(96)90144-0 1:STN:280:DyaK287osFamsQ%3D%3D (Pubitemid 26112171)
12. CW Wu CA Hsiung SS Lo, et al. 2006 Nodal dissection for patients with gastric cancer: a randomized controlled trial Lancet Oncol 7 309 315 16574546 10.1016/S1470-2045(06)70623-4 1:CAS:528:DC%2BD28Xnslaru7s%3D
13. M Sasako P McCulloch T Kinoshita K Maruyama 1995 New method to evaluate the therapeutic value of lymph node dissection for gastric cancer Br J Surg 82 346 351 7796005 10.1002/bjs.1800820321 1:STN:280:DyaK2Mzhs1ersQ%3D%3D
14. M Sasako T Sano S Yamamoto, et al. 2008 D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer N Engl J Med 359 453 462 18669424 10.1056/NEJMoa0707035 1:CAS:528:DC%2BD1cXpt1Shu7Y%3D
15. JA Ajani W Rodriguez G Bodoky, et al. 2010 Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial J Clin Oncol 28 1547 1553 20159816 10.1200/JCO.2009.25.4706 1:CAS:528:DC%2BC3cXltFGhtr0%3D
16. W Koizumi H Narahara T Hara, et al. 2008 Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D
17. N Boku S Yamamoto K Shirao, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study Lancet Oncol 10 1063 1069 19818685 10.1016/S1470- 2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI
18. Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14:72-80.
19. S Sakuramoto M Sasako T Yamaguchi, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 17978289 10.1056/NEJMoa072252 1:CAS:528:DC%2BD2sXht1Kit7bI (Pubitemid 350044801)